AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$BIIB

Freedom Broker raises Biogen stock price target on strong results

Freedom Broker raised its price target on Biogen (BIIB) to $275 from $255, citing strong quarterly results and resilient portfolio performance. The stock is near its 52-week high of $258.78. Biogen reported adjusted earnings of $2.62 per share on revenue of $2.8 billion, exceeding expectations. Several analysts have revised earnings upwards and raised price targets.

Original reporting
investing.com
Published Oct 29, 2026, 5:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BIIB
Bullish
high confidence
Mentioned
$BIIB
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BIIBBullishHigh
01

Why it matters

The earnings beat and raised targets provide fresh bullish catalysts for the stock.

02

Market read

Biogen's earnings beat and analyst upgrades create a short‑term buying opportunity.

03

What to watch

Potential headwinds in Q4 and reliance on Apellis integration could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Freedom Broker upgraded Biogen to Buy with a higher price target after reporting Q3 2026 results that beat consensus.

Company-level read

Ticker impact

$BIIBBullishHigh confidence
Context

Freedom Broker raised Biogen's price target to $275 and reported strong Q3 2026 earnings beating expectations.

Expected impact

likely upside as market prices in higher target and earnings beat

Evidence & confidence

Target raise to $275 and EPS $2.62 vs $2.02 estimate indicate strong fundamentals, prompting buying interest.

Market effects

Sector

Positive earnings may lift the biotech sector and rare‑disease peers.

Regional

U.S. biotech stocks could see modest gains.

Global

Limited to investors focused on Biogen and related biotech equities.

Counterpoint

What could challenge this read

Some investors may question sustainability of one‑time benefits and high valuation multiples.

Key entities

  • company
    Biogen Inc.

    U.S. biotech firm reporting strong Q3 2026 earnings.

  • analyst
    Freedom Broker

    Research firm that raised the price target and rating.

Read at source← All news

Related articles

OCT 30
$BIIBMed

Biogen (BIIB) Receives a Buy from TD Cowen

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB) with a $250.00 price target. Biogen's shares closed at $244.05. The company reported Q3 revenue of $2.8B and a net loss of $20.6M, down from last year's $2.45B revenue and $466.5M profit. Insider sentiment is negative, with recent sales by directors.

theglobeandmail.com2 min
OCT 29
$BIIBHighAI 9/10

Biogen Q3 Revenue Surges to $2.8 Billion as New Drugs Deliver; Company Raises Full-Year EPS Floor

Biogen (BIIB) reported Q3 revenue of $2.8B, up 11% YoY, beating estimates. Adjusted EPS of $2.62 also surpassed expectations. The company raised its full-year EPS guidance to $12.20-$13.00. Growth products, including rare disease and Alzheimer's drugs, drove revenue growth, while MS drugs declined. R&D and SG&A expenses increased significantly. Biogen expects mid-single-digit revenue growth in 2026.

finance.biggo.com3 min
OCT 29
$BIIBMedAI 8/10

Biogen Inc (BIIB) (Q3 2026) Earnings Call Highlights: Revenue Climbs 11% as Growth

Biogen Inc (BIIB) reported Q3 2026 revenue up 11% to $3.2B, but GAAP EPS was a loss of $0.14 due to acquisition-related charges. VUMERITY revenue declined 11% YoY, while Apellis acquisition increased OPEX by 27%. Biogen updated its PREVAIL trial design to a one-year eGFR endpoint. Management discussed market potential for felzartamab in AMR and litifilimab in SLE/CLE, and noted strong uptake of IQLIK and SPINRAZA high dose.

finance.yahoo.com3 min
OCT 28
$BIIBHighAI 8/10

Biogen Q3 Earnings Call Highlights

Biogen reported Q3 earnings, highlighting a 23% YoY increase in SPINRAZA revenue to $461M, driven by patient conversions. LEQEMBI revenue rose 67% to $202M, while SKYCLARYS increased 34% to $178M. TYSABRI revenue grew 1% to $437M, and VUMERITY declined 11% to $192M. Biogen raised its 2026 EPS guidance to $12.20-$13.00 and expects key pipeline data readouts in the coming months.

finance.yahoo.com2 min